T. Rowe Price Associates
SLRN

T. Rowe Price Associates’s ACELYRIN SLRN Stock Holding History

T. Rowe Price Associates’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-34,515
Closed -$86K – 3140
2025
Q1 		$86K Buy
34,515
+7,777
+29% +$18.5K ﹤0.01% 2858
2024
Q4 		$84K Buy
26,738
+3,266
+14% +$15.8K ﹤0.01% 2870
2024
Q3 		$116K Buy
23,472
+528
+2% +$2.73K ﹤0.01% 2793
2024
Q2 		$102K Buy
22,944
+2,241
+11% +$10.5K ﹤0.01% 2757
2024
Q1 		$140K Buy
+20,703
New +$157K ﹤0.01% 2713
2023
Q4 		– Sell
-458,261
Closed -$4.66M – 2928
2023
Q3 		$4.66M Sell
458,261
-431,121
-48% -$9.16M ﹤0.01% 1194
2023
Q2 		$18.6M Buy
+889,382
New +$18.2M ﹤0.01% 954

Other funds holding SLRN

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

T. Rowe Price Associates's SLRN Position: Q2 2025 in Review

T. Rowe Price Associates sold out of ACELYRIN (SLRN) in Q2 2025, closing a stake of 34,515 shares — an estimated $86K sold.

T. Rowe Price Associates first reported a position in SLRN in Q2 2023 and held it in 7 quarters. The position peaked at $18.6M in Q2 2023. 2 funds tracked by Wall St. Rank hold SLRN as of Q2 2025.

  • T. Rowe Price Associates reported no remaining ACELYRIN position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 34,515 ACELYRIN shares in Q2 2025, an estimated $86K.
  • T. Rowe Price Associates first reported a position in ACELYRIN in Q2 2023 and held it in 7 quarters.
  • T. Rowe Price Associates's ACELYRIN position peaked at $18.6M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.